---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-009906"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:43:44.599213+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics effectuates 1-for-16 reverse stock split effective Feb 7, 2025

## Summary
- Board approved 1-for-16 reverse split on Jan 29; stockholders approved at Jan 28 special meeting.
- Every 16 shares of common stock reclassified into 1 share; no fractional shares, cash paid for fractions.
- Split-adjusted trading begins Feb 10 under existing symbol BTAI; new CUSIP 09075P204.
- Proportional adjustments to equity plans, stock options, warrants, and other convertible securities.
- Reverse split does not affect authorized shares or par value; shares remain fully paid and non-assessable.

## SEC filing metadata
- accession: 0001104659-25-009906
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465925009906/0001104659-25-009906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465925009906/tm255604d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-009906
- JSON: https://secwatch.observer/filing/0001104659-25-009906.json
- Plain text: https://secwatch.observer/filing/0001104659-25-009906.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.